Tokyo, Aug. 2 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058660) titled 'Real-world Outcomes in Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL) Treated with Epcoritamab in Japan' on Aug. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Genmab US, Inc.
Condition:
Condition - Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to evaluate the effectiveness of epcoritamab in patients with 3L+ R/R LBCL (including diffuse large B-cell lymphoma [DLBCL], high-grade B-cell lymphoma [HGBCL], primary mediastinal large B-cell lymphoma [PMBCL], an...